Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 December;108(6) > Minerva Medica 2017 December;108(6):489-95



Publication history
Cite this article as


A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878




Minerva Medica 2017 December;108(6):489-95

DOI: 10.23736/S0026-4806.17.05320-4


language: English

Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a “real world” study by 13C-octanoic Acid Breath Test

Gian P. CAVIGLIA 1 , Carlo SGUAZZINI 2, Fabio CISARÒ 2, Davide G. RIBALDONE 2, Chiara ROSSO 1, Sharmila FAGOONEE 3, Antonina SMEDILE 1, 2, Giorgio M. SARACCO 1, 2, Marco ASTEGIANO 2, Rinaldo PELLICANO 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy; 3 Institute for Biostructures and Bioimages CNR c/o Molecular Biotechnology Center, University of Turin, Turin, Italy


BACKGROUND: Gastric motility is a key-factor in the pathogenesis of functional dyspepsia (FD). 13C-octanoic Acid Breath Test (OBT) is a tool used for measuring gastric emptying time in clinical setting. We aimed to investigate the variation in FD symptoms and OBT parameters after treatment with buspirone, amitriptyline or clebopride.
METHODS: Between Jan-2007 and Dec-2014, we enrolled 59 patients with FD unresponsive to first-line therapy with proton pump inhibitors and/or domperidone that underwent OBT before and after 3 months of buspirone (N.=32), amitriptyline (N.=16) or clebopride (N.=11) treatment.
RESULTS: Early satiation severity was positively correlated with gastric half emptying time (t1/2) (r=0.3789, P=0.003) and gastric lag phase (r=0.3371, P=0.011), and negatively correlated with gastric emptying coefficient (r=-0.3231, P=0.015). A reduction in t1/2 measurement in association to postprandial fullness, and early satiation severity improvement was observed (P=0.009, P=0.005 and P<0.001, respectively). Patients treated with buspirone obtained both a decrease in t1/2 (P=0.005) and an amelioration in early satiation (P=0.001). Patients under amitriptyline treatment experienced an improvement in postprandial fullness (P=0.046), whereas no variation was reported in patients treated with clebopride.
CONCLUSIONS: Patients with FD, non-responders to first-line therapy and reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapies.

KEY WORDS: Breath tests - Dyspepsia - Gastrointestinal motility

top of page

Publication History

Issue published online: November 2, 2017
Article first published online: July 12, 2017
Manuscript accepted: June 24, 2017
Manuscript received: June 22, 2017

Cite this article as

Caviglia GP, Sguazzini C, Cisarò F, Ribaldone DG, Rosso C, Fagoonee S, et al. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a “real world” study by 13C-octanoic Acid Breath Test. Minerva Med 2017;108:489-95. DOI: 10.23736/S0026-4806.17.05320-4

Corresponding author e-mail